Company profile: Natrogen Therapeutics
1.1 - Company Overview
Company description
- Provider of Natura-alpha, a small-molecule oral compound undergoing clinical trials for patients with ulcerative colitis.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Natrogen Therapeutics
PureTech Health
HQ: United States
Website
- Description: Provider of biopharma therapies and platforms, including KarXT for schizophrenia (xanomeline + trospium), LYT-100 (deuterated pirfenidone) for idiopathic pulmonary fibrosis, LYT-200 (anti-galectin-9) for hematological malignancies and solid tumors, SPT-300 (oral allopregnanolone) for neurological and neuropsychiatric conditions, plus Vedanta's microbiome-based oral therapies and Entrega's hydrogel-enabled oral biologics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PureTech Health company profile →
Sucampo Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialized biopharmaceuticals addressing unmet medical needs, with marketed products AMITIZA for chronic constipation and IBS-C in adults and RESCULA in Japan for lowering intraocular pressure in glaucoma or ocular hypertension, and a late-stage pipeline including VTS-270 for Niemann-Pick Disease Type C and CPP-1X/sulindac for Familial Adenomatous Polyposis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sucampo Pharmaceuticals company profile →
Kither Biotech
HQ: Italy
Website
- Description: Provider of pharmaceutical drug development targeting chronic inflammatory diseases, with inhaled therapies such as KIT2014, a cAMP-modulating peptide add-on for cystic fibrosis that enhances CFTR function, reduces mucus, and limits airway inflammation, and KITCL27, an inhaled PI3K-inhibitor prodrug for idiopathic pulmonary fibrosis activated in target cells to minimize systemic side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kither Biotech company profile →
Delinia
HQ: United States
Website
- Description: Provider of novel therapeutics for autoimmune and inflammatory diseases, with a lead program focused on a molecule that selectively potentiates and expands regulatory T cells (Tregs), the immune cells critical to maintaining self-tolerance and immune system homeostasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delinia company profile →
Epiva
HQ: United States
Website
- Description: Provider of immuno-microbiome therapeutics, developing immunobiotic therapeutics through a platform from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epiva company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Natrogen Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Natrogen Therapeutics
2.2 - Growth funds investing in similar companies to Natrogen Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Natrogen Therapeutics
4.2 - Public trading comparable groups for Natrogen Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →